

CURRICULUM VITAE

Nina Shah, M.D.

PRESENT TITLE AND AFFILIATION

Primary Appointment

Professor of Clinical Medicine, Department of Medicine, The University of California San Francisco, San Francisco, CA

Dual/Joint/Adjunct Appointment

N/A

CITIZENSHIP

United States

HOME ADDRESS

19 Anchor Lane
San Carlos, CA 94070

OFFICE ADDRESS

400 Parnassus Ave.
4th Floor
San Francisco, CA 94143
Email: nina.shah@ucsf.edu

EDUCATION

Degree-Granting Education

Harvard University, Cambridge, MA, BA, 1998, Psychology & Biology (Cognitive Neuroscience)
New York University School of Medicine, New York, NY, MD, 2002, Doctorate of Medicine

Postgraduate Training

Residency, Internal Medicine, Columbia University Medical Center, New York City, NY, Dr. Nicholas Fieback, 6/2002-6/2005
Post-Doctoral Research Fellow, Medicine, Columbia University Medical Center, New York City, NY, Dr. Raphael Clynes, 7/2005-6/2007
Hematology-Oncology, Hematology/Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, Dr. Robert Wolff, 7/2007-7/2010

CREDENTIALS

Board Certification

American Board of Internal Medicine - Internal Medicine, 264796, 2005-2015
American Board of Internal Medicine - Oncology, 2020-2030
American Board of Internal Medicine - Hematology, 2012-2022

Licensures

Active

Medical Board of California C145564

Inactive

Texas Medical Board, TX, M8335, 11/2007-8/2017
Medical License, NY, 230482, 2003-2005

EXPERIENCE/SERVICE

Academic Appointments

Associate Professor of Clinical Medicine, Department of Medicine, The University of California San Francisco, San Francisco, CA 1/2017-7/2020

Associate Professor, Department of Stem Cell Transplantation, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2016-12/2016

Assistant Professor, Department of Stem Cell Transplantation, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 7/2010-8/2016

Administrative Appointments/Responsibilities

Educational Liaison, Cancer Hematology and Immunology Program, University of California San Francisco, San Francisco, CA; 2020-present

Medical Director, Stem Cell Transplantation Center, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 10/2014-10/2016

Other Appointments/Responsibilities

Clinical Specialist, The University of Texas MD Anderson Cancer Center, Houston, TX, 2008-2010

Endowed Positions

N/A

Consultantships

Genentech, Seattle Genetics, Oncopeptides, Karoypharm, Surface Oncology, Precision biosciences, GSK, Nektar, Amgen, Indapta Therapeutics, Sanofi, BMS, CareDx

Military or Other Governmental Service

N/A

Institutional Committee Activities

MD Anderson Clinical Research Committee, Member, 2011-2016

MD Anderson Pharmacy and Therapeutics Committee, Member, 2012

MD Anderson Physician Advisory Board, Member, 2013-present

MD Anderson ICD-10 Implementation Committee, Member, 2013-2015

MD Anderson Joint Hematology Quarterly Conference with Hospital Israelita Albert Einstein (HIAE), Member, 2013-2016

MD Anderson Department of Cancer Medicine Women Faculty & Fellows Initiatives Advisory Council, Panelist, 1/2013-2016

MD Anderson Standardized Discharge Process Committee, Member, 2014-2016

MD Anderson Medical Quality Planning Committee, Member, 2014-present

MD Anderson Electronic Medical Record/ EPIC Subject Matter Expert and Department Clinical Build Team, Member, 2014-2016

MD Anderson Committee for Deficiency Tracking and Review of Medical Documentation Penalty Policy, Member, 2015-2016

MD Anderson Agency for Healthcare Research and Quality (AHRQ) Analysis Committee, Member, 2015-2016

UCSF Research Retreat Planning Committee 2017

UCSF Malignant Hematology Faculty Search Committee, Chair, 2017-2020

UCSF Institutional Review Board 2019-present

HONORS AND AWARDS

Alfred B. Kornblut Medical Scholarship, New York University School of Medicine, 2001

Clark Medical Memorial Scholarship, New York University School of Medicine, 2001

Alpha Omega Alpha Medical Honor Society, New York University School of Medicine, 2002

Augusta Landes Packer Award, New York University School of Medicine, 2002

New York University School of Medicine Alumni Award, New York University School of Medicine, 2002

American Association for Cancer Research/American Society of Clinical Oncology Methods in Clinical Cancer Research Workshop, U. T. M. D. Anderson Cancer Center, 2008

Clifton D. Howe Award for Clinical Excellence, U. T. M. D. Anderson Cancer Center, 2008

Paul Calabresi Clinical Oncology Award Program, Columbia University, 2008-2012

American Society of Hematology Clinical Research Training Institute, U. T. M. D. Anderson Cancer Center, 2009

Lyndon B. Johnson Medical Oncology Service Fellow of the Year, U. T. M. D. Anderson Cancer Center, 2009

The Janice Davis Singletary Fellowship for Lymphoma Research, U. T. M. D. Anderson Cancer Center, 2009

UCSF Hematology-Oncology Fellowship Marc A. Shuman Mentoring Award, 2020

SERVICE TO PROFESSIONAL ORGANIZATIONS

2010 - 2012	American Society of Hematology Clinical Research Training Institute	Steering Committee
2012 - present	American Society of Blood and Marrow Transplantation	Committee on Practice Guidelines
2013 - present	Blood and Marrow Transplant Clinical Trials Network	Multiple Myeloma Intergroup Committee
2014 - present	Blood and Marrow Transplant Clinical Trials Network	BMT CTN 0702 Clinical Trial Endpoint Review Committee
2015 - 2017	American Society of Hematology Clinical Research Training Institute	Faculty
2017 - 2017	American Society of Hematology Daily News Editorial Board	Faculty
2017 - 2017	Best of ASCO (American Society of Clinical Oncology)	Faculty
2019 - 2023	American Society of Hematology Scientific Committee on Plasma Cell Neoplasia	Committee member
2018 - 2022	Center for International Blood and Marrow Transplant Research Plasma Cell Disorder and Adult Solid Tumor Working Committee	Committee member
2018 - present	Multiple Myeloma Research Foundation Immune Steering Committee	Applied Cellular Therapy Co-Lead
2019 - present	Society for Immunotherapy of Cancer Multiple Myeloma Subcommittee	Co-chair
2019 - 2019	American Society of Hematology Education Program	Session Chair

2019 - 2020	American Society of Hematology Friday Scientific Workshop: Immune Profiling and Minimal Residual Testing in Multiple Myeloma	Steering Committee and Session Chair
2020-present	Multiple Myeloma Research Consortium Steering Committee	Committee member

RESEARCH

Grants and Contracts

Funded

Principal Investigator, Identification of Immunomodulatory Effects of Azacitidine in Enhancing the Cytotoxicity of Daratumumab in Patients with Relapsed Refractory Multiple Myeloma. Research Evaluation and Allocation Committee (REAC) Award, University of California San Francisco 1/1/2021-12/31/2021; (\$50,000).

Other

N/A

Completed

Principal Investigator, Phase I/II study of umbilical cord blood-derived natural killer cells in conjunction with high dose chemotherapy and transplant for patients with multiple myeloma, CS2012-00036486LK 01, Celgene, 12/31/2012-12/30/2015, \$211,105 (\$70,368/year)

Co-Principal Investigator, 1%, High Risk Myeloma Moonshot Program, MD Anderson Cancer Center, PI - Orlowski, 11/2014-12/2016 (\$165,230/year)

Research Scholar, 75%, Ex Vivo Expanded Umbilical Cord Blood Natural Killer Cells as a Novel Therapeutic for Multiple Myeloma, K12 CA088084, NIH/NCI, PI - Robert Bast, MD, 8/30/2009-8/31/2012, \$214,386 (\$71,462/year)

Co-Investigator, Mechanisms of Symptoms of Multiple Myeloma and Its Therapy, P01 CA124787-04, NIH/NCI, PI - Charles Cleeland, M.D., 9/1/2011-8/31/2013 (\$183,261/year)

Principal Investigator, 1%, Umbilical Cord Blood-derived natural killer cell therapy for multiple myeloma, Stading-Younger Cancer Research Foundation, 2/1/2014-1/31/2019 (\$68,000/year)

Not Funded

N/A

Protocols

Funded- current

Co-National Principal Investigator, BMT CTN Protocol 1401: Phase II Multicenter Trial of Single Autologous Hematopoietic Cell Transplant Followed by Lenalidomide Maintenance for Multiple Myeloma with or without Vaccination with Dendritic Cell (DC)/Myeloma Fusions, NMDP

Institutional Principal Investigator, CC17256: Phase 2, Randomized, Open-Label Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma Eligible for High-Dose Chemotherapy and Autologous Stem Cell Transplantation

Institutional Principal Investigator, CC 17704: A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma

Institutional Principal Investigator CC177016: A phase 2, Multicenter Study to Determine the Efficacy and Safety of BB2121 in Subjects With Relapsed and Refractory Multiple Myeloma

Institutional Principal Investigator, CC 18951: A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-001, an anti-CD74 Antibody Drug Conjugate, in Patients with Advanced B-Cell Malignancies

Institutional Principal Investigator, CC 187016: A phase 2, Multicenter Study to Determine the Efficacy and Safety of BB2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects with High-Risk Multiple Myeloma Having Progressed within One Year of Initial Treatment (KarMMa-2)

Institutional Principal Investigator CC 19259/UCHMC1809:Phase II study of the combination of daratumumab, ixazomib, pomalidomide, and dexamethasone as salvage therapy in relapsed/refractory multiple myeloma

Institutional and National Principal Investigator CC 192513:A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant

Institutional Principal Investigator CC 197011: A Multicenter, Phase 1, Open-label, Dose-escalation and Expansion Study of TNB-383B, a Bispecific Antibody Targeting BCMA in Subjects with Relapsed or Refractory Multiple Myeloma

Institutional Principal Investigator CC 197012: Open-Label, Multicenter, Single Ascending Dose Study to Assess the Safety of P-BCMA-101 in Subjects with Relapsed / Refractory Multiple Myeloma (MM) Followed by a Phase 2 Assessment of Response and Safety (PRIME)

Institutional Principal Investigator CC 197019: A Phase 1, Open-Label, Multi-Center Dose Escalation and Dose Expansion Study of NKTR-255 as a Single Agent in Relapsed or Refractory Hematological Malignancies and in Combination with Daratumumab as a Salvage Regimen for Multiple Myeloma

Institutional Principal Investigator CC 197022 A Phase 1, Open-Label, Multicenter Study to Evaluate the Safety of BB2121 in Subjects with High Risk, Newly Diagnosed Multiple Myeloma (NDMM) (KarMMa-4)

Principal Investigator CC 20251: Phase II Study of Daratumumab in Combination with Azacitidine and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Daratumumab

Funded - completed

Principal Investigator, Randomized phase II trial of two stem cell doses to reduce transplant induced symptom burden in high risk patients with multiple myeloma or amyloidosis, 2005-0601, 2005-2014

Principal Investigator, Phase I/II study of umbilical cord blood-derived natural killer cells in conjunction with high dose chemotherapy and autologous stem cell transplant for patients with multiple myeloma, 2011-0379, 2011-2016

Co-Principal Investigator, A phase II randomized study of the efficacy of minocycline vs. placebo to reduce symptom burden during maintenance therapy for multiple myeloma, 2012-0413, 2012-2016

Co-Principal Investigator, Phase II Multicenter Trial of Single Autologous Hematopoietic Cell Transplant Followed by Lenalidomide Maintenance for Multiple Myeloma with or without Vaccination with Dendritic Cell /Myeloma Fusions, BMT CTN 1401, 2016-present

Patents and Technology Licenses

Patents

N/A

Technology Licenses

N/A

Grant Reviewer/Service on Study Sections

American Society of Hematology Clinical Research Training Institute Study Section, NIH, reviewer, 2011-2014, 2016-2017

PUBLICATIONS

Peer-Reviewed Articles

1. Taylor C, Hershman D, **Shah N**, Suci-Foca N, Petrylak DP, Taub R, Vahdat L, Cheng B, Pegram M, Knutson KL, Clynes R. Augmented HER-2specific immunity during treatment with trastuzumab and chemotherapy. *Clin Cancer Res* 13(17):5133-5143, 9/2007. PMID: 17785568.
2. Yang H, Robinson SN, Lu J, Decker WK, Xing D, Steiner D, Parmar S, **Shah N**, Champlin RE, Munsell M, Leen A, Bollard C, Simmons PJ, Shpall EJ. CD3+ and/or CD14+ depletion from cord blood mononuclear cells before ex vivo expansion culture improves total nucleated cell and CD34+ cell yields. *Bone Marrow Transplant* 45(6):1000-1007, 6/2010. e-Pub 10/2009. PMID: 19838220.
3. Xing D, Ramsay AG, Gribben JG, Decker WK, Burks JK, Munsell M, Li S, Robinson SN, Yang H, Steiner D, **Shah N**, McMannis JD, Champlin RE, Hosing C, Zweidler-McKay PA, Shpall EJ, Bollard CM. Cord Blood Natural Killer Cells Exhibit Impaired Lytic Immunological Synapse Formation That is Reversed with IL-2 Exvivo Expansion. *J Immunother* 33(7):684-696, 9/2010. PMID: PMC3530422.
4. **Shah N**, Lonial S. Evidence-based mini-review: treatment options for patients with relapsed/refractory myeloma previously treated with novel agents and high-dose chemotherapy and autologous stem-cell transplantation. *Hematology Am Soc Hematol Educ Program* 2010:310-3, 2010. PMID: PMC4086196.
5. **Shah N**, Decker WK, Lapushin R, Xing D, Robinson SN, Yang H, Parmar S, Tung SS, O'Brien S, Fernandez-Viña M, Shpall EJ, Wierda WG. HLA homozygosity and haplotype bias among patients with chronic lymphocytic leukemia: implications for disease control by physiological immune surveillance. *Leukemia* 25(6):1036-9, 6/2011. e-Pub 2/2011. PMID: 21350559.
6. Yang H, Robinson SN, Nieto Y, Jones RJ, Gocke CD, Lu J, Giralt SA, Jones RB, Decker WK, Xing D, Steiner D, Champlin RE, McMannis JD, Ng J, Thomas MW, **Shah N**, Andersson BS, Parmar S, Shpall EJ. Ex vivo graft purging and expansion of autologous blood progenitor cell products from patients with multiple myeloma. *Cancer Res* 71(14):5040-9, 7/2011. e-Pub 6/2011. PMID: 21646477.
7. Bashir Q, **Shah N**, Parmar S, Wei W, Rondon G, Weber DM, Wang M, Orlowski RZ, Thomas SK, Shah J, Qureshi SR, Dinh YT, Popat U, Anderlini P, Hosing C, Giralt S, Champlin RE, Qazilbash MH. Feasibility of autologous hematopoietic stem cell transplant in patients aged greater than 70 years with multiple myeloma. *Leuk Lymphoma* 53(1):118-22, 1/2012. e-Pub 8/2011. PMID: 21780997.
8. **Shah N**, Cabanillas F, McIntyre B, Feng L, McLaughlin P, Rodriguez MA, Romaguera J, Younes A, Hagemeister FB, Kwak L, Fayad L. Prognostic value of serum CD44, ICAM-1 and VCAM-1 levels in patients with indolent non-Hodgkin lymphomas. *Leuk Lymphoma* 53(1):50-6, 1/2012. e-Pub 10/2011. PMID: PMC4104165.
9. Bashir Q, Khan H, Orlowski RZ, Amjad AI, **Shah N**, Parmar S, Wei W, Rondon G, Weber DM, Wang M, Thomas SK, Shah JJ, Qureshi SR, Dinh YT, Popat U, Anderlini P, Hosing C, Giralt S, Champlin RE, Qazilbash MH. Predictors of prolonged survival after allogeneic

- hematopoietic stem cell transplantation for multiple myeloma. *Am J Hematol* 87(3):272-6, 3/2012. e-Pub 1/2012. PMID: PMC3894831.
10. Sharma M, Khan H, Thall PF, Orlowski RZ, Bassett RL, **Shah N**, Bashir Q, Parmar S, Wang M, Shah JJ, Hosing CM, Popat UR, Giralt SA, Champlin RE, Qazilbash MH. A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid. *Cancer* 118(9):2507-15, 5/2012. e-Pub 9/2011. PMID: PMC4015116.
 11. **Shah N**, Ahmed F, Bashir Q, Qureshi S, Dinh Y, Rondon G, Wen S, Thall P, Khan H, Giralt S, Champlin R, Qazilbash MH. Durable Remission With Salvage Second Autotransplants in Patients with Multiple Myeloma. *Cancer* 118(14):3549-3555, 7/2012. e-Pub 11/2011. PMID: PMC4038445.
 12. Beitinjaneh AM, Saliba R, Bashir Q, **Shah N**, Parmar S, Hosing C, Popat U, Anderlini P, Dinh Y, Qureshi S, Rondon G, Champlin RE, Giralt SA, Qazilbash MH. Durable responses after donor lymphocyte infusion for patients with residual multiple myeloma following non-myeloablative allogeneic stem cell transplant. *Leuk Lymphoma* 53(8):1525-1529, 8/2012. e-Pub 3/2012. PMID: 22242817.
 13. Nieto Y, Thall P, Valdez B, Andersson B, Popat U, Anderlini P, Shpall EJ, Bassett R, Alousi A, Hosing C, Kebriaei P, Qazilbash M, Frazier E, Gulbis A, Chancoco C, Bashir Q, Ciurea S, Khouri I, Parmar S, **Shah N**, Worth L, Rondon G, Champlin R, Jones RB. High-Dose Infusional Gemcitabine Combined with Busulfan and Melphan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphoid Malignancies. *Biol Blood Marrow Transplant* 18(11):1677-1686, 11/2012. e-Pub 5/2012. PMID: PMC4010147.
 14. de Lima M, McNiece I, Robinson SN, Munsell M, Eapen M, Horowitz M, Alousi A, Saliba R, McMannis JD, Kaur I, Kebriaei P, Parmar S, Popat U, Hosing C, Champlin R, Bollard C, Molldrem JJ, Jones RB, Nieto Y, Andersson BS, **Shah N**, Oran B, Cooper LJ, Worth L, Qazilbash MH, Korbling M, Rondon G, Ciurea S, Bosque D, Maewal I, Simmons PJ, Shpall EJ. Cord-blood engraftment with ex vivo mesenchymal-cell coculture. *N Engl J Med* 367(24):2305-15, 12/2012. PMID: PMC3805360.
 15. Decker WK, **Shah N**, Xing D, Lapushin R, Li S, Robinson SN, Yang H, Parmar S, Halpert MM, Keating MJ, Gribben JG, Molldrem JJ, Shpall EJ, Wierda WG. Generation of Functional CLL-Specific Cord Blood CTL Using CD40-Ligated CLL APC. *PLoS One* 7(12):e51390, 2012. e-Pub 12/2012. PMID: PMC3526610.
 16. Nieto Y, Popat U, Anderlini P, Valdez B, Andersson B, Liu P, Hosing C, Shpall EJ, Alousi A, Kebriaei P, Qazilbash M, Parmar S, Bashir Q, **Shah N**, Khouri I, Rondon G, Champlin R, Jones RB. Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome. *Biol Blood Marrow Transplant* 19(3):410-7, 3/2013. e-Pub 11/2012. PMID: PMC4077191.
 17. Aung FM, Lichtiger B, Bassett R, Liu P, Alousi A, Bashier Q, Ciurea SO, de Lima MJ, Hosing C, Kebriaei P, Nieto Y, Oran B, Parmar S, Qazilbash M, **Shah N**, Khouri I, Champlin RE, Popat U. Incidence and natural history of pure red cell aplasia in major ABO-mismatched haematopoietic cell transplantation. *Br J Haematol* 160(6):798-805, 3/2013. e-Pub 1/2013. PMID: PMC4078723.
 18. Vichaya EG, Wang XS, Boyette-Davis JA, Mendoza TR, He Z, Thomas SK, **Shah N**, Williams LA, Cleeland CS, Dougherty PM. Subclinical pretreatment sensory deficits appear to predict the development of pain and numbness in patients with multiple myeloma undergoing chemotherapy. *Cancer Chemother Pharmacol* 71(6):1531-40, 6/2013. e-Pub 3/2013. PMID: PMC3669643.
 19. Sasaki K, Lu G, Saliba RM, Bashir Q, Hosing C, Popat U, **Shah N**, Parmar S, Dinh Y, Ahmed S, Shpall EJ, Kebriaei P, Shah JJ, Orlowski RZ, Champlin R, Qazilbash MH. Impact of the Outcome of Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. *Biol Blood Marrow Transplant* 19(8):1227-32, 8/2013. e-Pub 5/2013. PMID: PMC4150684.
 20. Bashir Q, Khan H, Thall PF, Liu P, **Shah N**, Kebriaei P, Parmar S, Oran B, Ciurea S, Nieto Y, Jones R, Hosing CM, Popat UR, Dinh YT, Rondon G, Orlowski RZ, Shah JJ, De Lima M, Shpall E, Champlin R, Giralt S, Qazilbash MH. A Randomized Phase II Trial of Fludarabine/Melphalan 100 versus Fludarabine/Melphalan 140 followed by Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Multiple Myeloma. *Biol Blood Marrow Transplant* 19(10):1453-8, 10/2013. e-Pub 7/2013. PMID: PMC4157818.

21. **Shah N**, Martin-Antonio B, Yang H, Ku S, Lee DA, Cooper LJ, Decker WK, Li S, Robinson SN, Sekine T, Parmar S, Gribben J, Wang M, Rezvani K, Yvon E, Najjar A, Burks J, Kaur I, Champlin RE, Bollard CM, Shpall EJ. Antigen Presenting Cell-Mediated Expansion of Human Umbilical Cord Blood Yields Log-Scale Expansion of Natural Killer Cells with Anti-Myeloma Activity. *PLoS One* 8(10):e76781, 2013. e-Pub 10/2013. PMID: PMC3800010.
22. Jones D, Vichaya EG, Wang XS, Williams LA, **Shah ND**, Thomas SK, Johnson VE, Champlin RE, Cleeland CS, Mendoza TR. Validation of the MD Anderson Symptom Inventory Multiple Myeloma Module. *J Hematol Oncol* 6(1):13, 2013. e-Pub 2/2013. PMID: PMC3598689.
23. Robinson SN, Thomas MW, Simmons PJ, Lu J, Yang H, Parmar S, Liu X, **Shah N**, Martin-Antonio B, Bollard C, Dotti G, Savoldo B, Cooper LJ, Najjar A, Rezvani K, Kaur I, McNiece IK, Champlin RE, Miller LP, Zweidler-McKay PA, Shpall EJ. Fucosylation with fucosyltransferase VI or fucosyltransferase VII improves cord blood engraftment. *Cytotherapy* 16(1):84-9, 1/2014. e-Pub 10/2013. PMID: PMC3883688.
24. Parmar S, Liu X, Tung SS, Robinson SN, Rodriguez G, Cooper LJ, Yang H, **Shah N**, Yang H, Konopleva M, Molldrem JJ, Garcia-Manero G, Najjar A, Yvon E, McNiece I, Rezvani K, Savoldo B, Bollard CM, Shpall EJ. Third Party Umbilical Cord Blood-Derived Regulatory T-cells Prevent Xenogenic Graft-versus-Host Disease. *Cytotherapy* 16(1):90-100, 1/2014. e-Pub 10/2013. PMID: PMC4124936.
25. Patel K, Nusrat M, **Shah N**, Bashir Q, Parmar S, Shah J, Thomas S, Weber D, Orlowski RZ, Champlin R, Qazilbash MH. Durable responses with autologous hematopoietic SCT in patients with POEMS syndrome. *Bone Marrow Transplant* 49(3):465-6, 3/2014. e-Pub 1/2014. PMID: 24419515.
26. Wang XS, Shi Q, **Shah ND**, Heijnen CJ, Cohen EN, Reuben JM, Orlowski RZ, Qazilbash MH, Johnson VE, Williams LA, Mendoza TR, Cleeland CS. Inflammatory Markers and Development of Symptom Burden in Patients with Multiple Myeloma during Autologous Stem Cell Transplantation. *Clin Cancer Res* 20(5):1366-74, 3/2014. e-Pub 1/2014. PMID: PMC3947467.
27. Liu X, Robinson SN, Setoyama T, Tung SS, D'Abundo L, Shah MY, Yang H, Yvon E, **Shah N**, Yang H, Konopleva M, Garcia-Manero G, McNiece I, Rezvani K, Calin GA, Shpall EJ, Parmar S. FOXP3 is a direct target of miR15a/16 in umbilical cord blood regulatory T cells. *Bone Marrow Transplant* 0(6):793-9, 6/2014. e-Pub 4/2014. PMID: PMC4080423.
28. Mehta RS, Di Stasi A, Hosing C, **Shah N**, Rezvani K, Alousi A, O'Brien S, Wierda W, Keating M, Shpall EJ. Lenalidomide-induced graft-vs.-Leukemia effect in a patient with chronic lymphocytic leukemia who relapsed after allogeneic stem cell transplant. *Clin Lymphoma Myeloma Leuk* 14(3):e105-9, 6/2014. e-Pub 12/2013. PMID: 24502832.
29. Parmar S, Kongtim P, Champlin R, Dinh Y, Elgharably Y, Wang M, Bashir Q, Shah JJ, **Shah N**, Popat U, Giralt SA, Orlowski RZ, Qazilbash MH. Auto-SCT improves survival in systemic light chain amyloidosis: a retrospective analysis with 14-year follow-up. *Bone Marrow Transplant* 49(8):1036-41, 8/2014. e-Pub 6/2014. PMID: 24887378.
30. **Shah N**, Rezvani K, Hosing C, Kebriaei P, Wierda W, Cooper L, Shpall E. Progress in novel cellular therapy options for chronic lymphocytic leukemia: the M D Anderson perspective. *Clin Lymphoma Myeloma Leuk* 14 Suppl:S18-22, 9/2014. PMID: 25486950.
31. Khoder A, Sarvaria A, Alsuliman A, Chew C, Sekine T, Cooper N, Mielke S, de Lavallade H, Muftuoglu M, Fernandez Curbelo I, Liu E, Muraro PA, Alousi A, Stringaris K, Parmar S, **Shah N**, Shaim H, Yvon E, Molldrem J, Rouce R, Champlin R, McNiece I, Mauri C, Shpall EJ, Rezvani K. Regulatory B cells are enriched within the IgM memory and transitional subsets in healthy donors but are deficient in chronic GVHD. *Blood* 124(13):2034-45, 9/2014. e-Pub 7/2014. PMID: PMC4186534.
32. Kosturakis AK, He Z, Li Y, Boyette-Davis JA, **Shah N**, Thomas SK, Zhang H, Vichaya EG, Wang XS, Wendelschafer-Crabb G, Kennedy WR, Simone DA, Cleeland CS, Dougherty PM. Subclinical Peripheral Neuropathy in Patients With Multiple Myeloma Before Chemotherapy Is Correlated With Decreased Fingertip Innervation Density. *J Clin Oncol* 32(28):3156-62, 10/2014. e-Pub 8/2014. PMID: PMC4171359.
33. Munoz J*, **Shah N***, Rezvani K, Hosing C, Bollard CM, Oran B, Olson A, Popat U, Molldrem J, McNiece IK, Shpall EJ. Concise review: umbilical cord blood transplantation: past, present,

- and future. *Stem Cells Transl Med* 3(12):1435-43, 12/2014. e-Pub 11/2014. PMID: PMC4250219.
34. Martin-Antonio B, Najjar A, Robinson SN, Chew C, Li S, Yvon E, Thomas MW, Mc Niece I, Orlowski R, Muñoz-Pinedo C, Bueno C, Menendez P, Fernández de Larrea C, Urbano-Ispizua A, Shpall EJ, **Shah N**. Transmissible cytotoxicity of multiple myeloma cells by cord blood-derived NK cells is mediated by vesicle trafficking. *Cell Death Differ* 22(1):96-107, 1/2015. e-Pub 8/2014. PMID: PMC4262774.
 35. Parmar S, Liu X, Najjar A, **Shah N**, Yang H, Yvon E, Rezvani K, McNiece I, Zweidler-McKay P, Miller L, Wolpe S, Blazar BR, Shpall EJ. Ex vivo fucosylation of 3rd party human regulatory T cells enhances anti-graft versus host disease potency in vivo. *Blood* 125(9):1502-6, 2/2015. e-Pub 11/2014. PMID: PMC4342362.
 36. Gul Z, Bashir Q, Cremer M, Yusuf SW, Gunaydin H, Arora S, Slone S, Nieto Y, Sherwani N, Parmar S, **Shah N**, Dinh YT, Hosing CM, Popat UR, Kebriaei P, Shpall EJ, Giralt SA, Champlin RE, Qazilbash MH. Short-term Cardiac Toxicity of Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. *Leuk Lymphoma* 56(2):1-8, 2/2015. e-Pub 7/2014. PMID: 24882259.
 37. Glitza IC, Lu G, Shah R, Bashir Q, **Shah N**, Champlin RE, Shah J, Orlowski RZ, Qazilbash MH. Chromosome 8q24.1/c-MYC Abnormality: A Marker for High-Risk Myeloma. *Leuk Lymphoma* 56(3):1-18, 3/2015. e-Pub 8/2014. PMID: PMC4333105.
 38. Shi Q, Wang XS, Li G, **Shah ND**, Orlowski RZ, Williams LA, Mendoza TR, Cleeland CS. Racial/ethnic disparities in inflammatory gene single-nucleotide polymorphisms as predictors of a high risk for symptom burden in patients with multiple myeloma 1 year after diagnosis. *Cancer* 121(7):1138-46, 4/2015. e-Pub 12/2014. PMID: PMC4368488.
 39. Popat U, Mehta RS, Rezvani K, Fox P, Kondo K, Marin D, McNiece I, Oran B, Hosing C, Olson A, Parmar S, **Shah N**, Andreeff M, Kebriaei P, Kaur I, Yvon E, de Lima M, Cooper LJ, Tewari P, Champlin RE, Nieto Y, Andersson BS, Alousi A, Jones RB, Qazilbash MH, Bashir Q, Ciurea S, Ahmed S, Anderlini P, Bosque D, Bollard C, Molldrem JJ, Chen J, Rondon G, Thomas M, Miller L, Wolpe S, Simmons P, Robinson S, Zweidler-McKay PA, Shpall EJ. Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation. *Blood* 125(19):2885-92, 5/2015. e-Pub 3/2015. PMID: PMC4424412.
 40. Kongtim P, Qazilbash MH, Shah JJ, Hamdi A, **Shah N**, Bashir Q, Wang M, Champlin R, Manasanch EE, Weber D, Orlowski RZ, Parmar S. High-dose therapy with auto-SCT is feasible in high-risk cardiac amyloidosis. *Bone Marrow Transplant* 50(5):668-72, 5/2015. e-Pub 3/2015. PMID: 25730192.
 41. Wang XS, Shi Q, Williams LA, **Shah ND**, Mendoza TR, Cohen EN, Reuben JM, Cleeland CS, Orlowski RZ. Longitudinal Analysis of Patient-Reported Symptoms Post-AuSCT and their Relationship to Inflammation in Patients with Multiple Myeloma. *Leuk Lymphoma* 56(5):1-18, 5/2015. e-Pub 11/2014. PMID: PMC4439386.
 42. Alousi AM, Brammer JE, Saliba RM, Andersson B, Popat U, Hosing C, Jones R, Shpall EJ, Khouri I, Qazilbash M, Nieto Y, **Shah N**, Ahmed S, Oran B, Al Atrash G, Ciurea S, Kebriaei P, Chen J, Rondon G, Champlin RE. Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies. *Biol Blood Marrow Transplant* 21(5):906-12, 5/2015. e-Pub 2/2015. PMID: 25667989.
 43. Thompson PA, Rezvani K, Hosing CM, Oran B, Olson AL, Popat UR, Alousi AM, **Shah ND**, Parmar S, Bollard C, Hanley P, Kebriaei P, Cooper L, Kellner J, McNiece IK, Shpall EJ. Umbilical cord blood graft engineering: challenges and opportunities. *Bone Marrow Transplant* 50 Suppl 2:S55-62, 6/2015. PMID: 26039209.
 44. Saliba RM, Rezvani K, Leen A, Jorgensen J, **Shah N**, Hosing C, Parmar S, Oran B, Olson A, Rondon G, Chen J, Martinez C, Hamdi A, Mehta RS, Chemaly RF, Saunders IM, Bollard CM, Shpall EJ. General and Virus-Specific Immune Cell Reconstitution after Double Cord Blood Transplantation. *Biol Blood Marrow Transplant* 21(7):1284-90, 7/2015. e-Pub 2/2015. PMID: 25708219.
 45. **Shah N**, Callander N, Ganguly S, Gul Z, Hamadani M, Costa L, Sengsayadeth S, Abidi M, Hari P, Mohty M, Chen YB, Koreth J, Landau H, Lazarus H, Leather H, Majhail N, Nath R,

- Osman K, Perales MA, Schriber J, Shaughnessy P, Vesole D, Vij R, Wingard J, Giralt S, Savani BN. Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Guidelines from the American Society for Blood and Marrow Transplantation. *Biol Blood Marrow Transplant* 21(7):1155-66, 7/2015. e-Pub 3/2015. PMID: 25769794.
46. El Fakih R, Fox P, Popat U, Nieto Y, **Shah N**, Parmar S, Oran B, Ciurea S, Kebriaei P, Hosing C, Ahmed S, Shah J, Orlowski R, Champlin R, Qazilbash M, Bashir Q. Autologous Hematopoietic Stem Cell Transplantation in Dialysis-Dependent Myeloma Patients. *Clin Lymphoma Myeloma Leuk* 15(8):472-6, 8/2015. e-Pub 3/2015. PMID: PMC4516682.
 47. **Shah N**, Shi Q, Williams LA, Mendoza TR, Wang XS, Reuben JM, Dougherty PM, Bashir Q, Qazilbash MH, Champlin RE, Cleeland CS, Giralt SA. Higher Stem Cell Dose Infusion after Intensive Chemotherapy Does Not Improve Symptom Burden in Older Patients with Multiple Myeloma and Amyloidosis. *Biol Blood Marrow Transplant*. e-Pub 8/2015. PMID: 26253006.
 48. Afrough A, Saliba RM, Hamdi A, El Fakih R, Varma A, Dinh YT, Rondon G, Cornelison AM, **Shah ND**, Bashir Q, Shah JJ, Hosing C, Popat U, Orlowski RZ, Champlin RE, Parmar S, Qazilbash MH. Outcome of Patients with Immunoglobulin Light-Chain Amyloidosis with Lung, Liver, Gastrointestinal, Neurologic, and Soft Tissue Involvement after Autologous Hematopoietic Stem Cell Transplantation. *Biol Blood Marrow Transplant* 21(8):1413-7, 8/2015. e-Pub 4/2015. PMID: 25842049.
 49. **Shah N**, Thall PF, Fox PS, Bashir Q, Shah JJ, Parmar S, Lin P, Kebriaei P, Nieto Y, Popat UR, Hosing CM, Cornelison A, Shpall EJ, Orlowski RZ, Champlin RE, Qazilbash MH. Phase I/II trial of lenalidomide and high-dose melphalan with autologous stem cell transplantation for relapsed myeloma. *Leukemia* 29(9):1945-8, 9/2015. e-Pub 2/2015. PMID: 25721897.
 50. Cornelison AM, Saliba RM, Afrough A, Dinh Y, Nieto Y, Bashir Q, **Shah N**, Parmar S, Hosing C, Popat U, Shpall E, Champlin R, Qazilbash MH. Autologous Hematopoietic Stem Cell Transplantation in Light Chain Amyloidosis (AL) With Renal Involvement. *Bone Marrow Transplant*. e-Pub 10/2015. PMID: 26479980.
 51. Oran B, Cao K, Saliba RM, Rezvani K, de Lima M, Ahmed S, Hosing CM, Popat UR, Carmazzi Y, Kebriaei P, Nieto Y, Rondon G, Willis D, **Shah N**, Parmar S, Olson A, Moore B, Marin D, Mehta R, Fernández-Viña M, Champlin RE, Shpall EJ. Better Allele-Level Matching Improves Transplant Related Mortality After Double Cord Blood Transplantation. *Haematologica* 100(10):1361-70, 10/2015. e-Pub 8/2015. PMID: PMC4591769.
 52. Thompson PA, Perera T, Marin D, Oran B, Popat U, Qazilbash M, **Shah N**, Parmar S, Rezvani K, Olson A, Kebriaei P, Anderlini P, Rondon G, Alousi A, Ciurea S, Champlin RE, Bajel A, Szer J, Shpall EJ, Ritchie D, Hosing C. Double Umbilical Cord Blood Transplantation (dUCB) is effective therapy for relapsed or refractory Hodgkin Lymphoma. *Leuk Lymphoma*:1-23. e-Pub 10/2015. PMID: 26472485.
 53. Kazmi SM, Nusrat M, Gunaydin H, Cornelison AM, **Shah N**, Kebriaei P, Nieto Y, Parmar S, Popat UR, Oran B, Shah JJ, Orlowski RZ, Champlin RE, Qazilbash MH, Bashir Q. Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated with High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation. *Clin Lymphoma Myeloma Leuk* 15(11):687-93, 11/2015. e-Pub 8/2015. PMID: PMC4644689.
 54. Nieto Y, Valdez BC, Thall PF, Ahmed S, Jones RB, Hosing C, Popat U, Shpall EJ, Qazilbash M, Gulbis A, Anderlini P, Alousi A, **Shah N**, Bashir Q, Liu Y, Oki Y, Hagemester F, Fanale M, Dabaja B, Pinnix C, Champlin R, Andersson BS. Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas. *Biol Blood Marrow Transplant* 21(11):1914-20, 11/2015. e-Pub 6/2015. PMID: 26071868.
 55. Pinnix CC, Shah JJ, Chuang H, Costelloe CM, Medeiros LJ, Wogan CF, Reed V, Smith GL, Milgrom S, Patel K, Huo J, Turturro F, Romaguera J, Fayad L, Oki Y, Fanale MA, Westin J, Nastoupil L, Hagemester FB, Rodriguez A, Qazilbash M, **Shah N**, Bashir Q, Ahmed S, Nieto Y, Hosing C, Rohren E, Dabaja B. Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma: A Single-Institution Review. *Clin Lymphoma Myeloma Leuk*. 2015 Dec 22. pii: S2152-2650(15)01435-4. doi: 10.1016/j.clml.2015.12.008. [Epub ahead of print].

56. Mehta RS, Rezvani K, Olson A, Oran B, Hosing C, **Shah N**, Parmar S, Armitage S, Shpall EJ. Novel Techniques for Ex Vivo Expansion of Cord Blood: Clinical Trials. *Front Med (Lausanne)*. 2015 Dec 11;2:89. doi: 10.3389/fmed.2015.00089. eCollection 2015.
57. Badar T, Cornelison AM, **Shah ND**, Bashir Q, Parmar S, Patel K, Hosing C, Popat U, Weber DM, Thomas SK, Shah JJ, Orłowski RZ, Champlin RE, Qazilbash MH. Outcome of Patients with Systemic Light chain (AL) Amyloidosis with Concurrent Renal and Cardiac Involvement. *Eur J Haematol*. 2016 Jan 16. doi: 10.1111/ejh.12736. [Epub ahead of print].
58. Jacobs RW, Saliba RM, Sasaki K, Farhan S, Armas A, **Shah ND**, Bashir Q, Qureshi S, Rondon G, Hosing C, Popat U, Parmar S, Shah JJ, Wang M, Weber DM, Thomas SK, Orłowski RZ, Champlin RE, Qazilbash MH. Outcome of Patients With Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation. *Clin Lymphoma Myeloma Leuk*. 2016 Jan;16(1):36-42. doi: 10.1016/j.clml.2015.11.005. Epub 2015 Dec 1.
59. Bigley AB, Rezvani K, **Shah N**, Sekine T, Balneger N, Pistillo M, Agha N, Kunz H, Bollard CM, O'Connor DP, Simpson RJ. Latent CMV infection enhances anti-tumor cytotoxicity through accumulation of NKG2C+ NK-cells in healthy humans. *Clin Exp Immunol*. 2016 Mar 3. doi: 10.1111/cei.12785. [Epub ahead of print].
60. Aung FM, Lichtiger B, Rondon G, Yin CC, Alousi A, Ahmed S, Andersson BS, Bashir Q, Ciurea SO, Hosing C, Jones R, Kebriaei P, Khouri I, Nieto Y, Oran B, Parmar S, Qazilbash M, **Shah N**, Shpall EJ, Champlin RE, Popat U. Pure Red Cell Aplasia in Major ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with Severe Pancytopenia.
61. Gaballa S, Saliba RM, Srour S, Lu G, Brammer JE, **Shah N**, Bashir Q, Patel K, Bock F, Parmar S, Hosing C, Popat U, Delgado R, Rondon G, Shah JJ, Manasanch EE, Orłowski RZ, Champlin R, Qazilbash M. Outcomes in patients with multiple myeloma with TP53 deletion after autologous hematopoietic stem cell transplant. *Am J Hematol*. 2016 Jul 15. doi: 10.1002/ajh.24487. [Epub ahead of print].
62. Gaballa S, Ge I, El Fakih R, Brammer JE, Kongtim P, Tomuleasa C, Wang SA, Lee D, Petropoulos D, Cao K, Rondon G, Chen J, Hammerstrom A, Lombardi L, Alatrash G, Korbling M, Oran B, Kebriaei P, Ahmed S, **Shah N**, Rezvani K, Marin D, Bashir Q, Alousi A, Nieto Y, Qazilbash M, Hosing C, Popat U, Shpall EJ, Khouri I, Champlin RE, Ciurea SO. Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation. *Cancer*. 2016 Jul 12. doi:10.1002/cncr.30180. [Epub ahead of print].
63. Nieto Y, Valdez BC, Thall PF, Jones RB, Wei W, Myers A, Hosing C, Ahmed S, Popat U, Shpall EJ, Qazilbash M, Gulbis A, Anderlini P, **Shah N**, Bashir Q, Alousi A, Oki Y, Fanale M, Dabaja B, Pinnix C, Champlin R, Andersson BS. Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma. *Cancer*. 2016 May 20. doi: 10.1002/cncr.30100. [Epub ahead of print].
64. Varma, A, Saliba RM, Torres HA, Afrough A, Hosing C, Khouri IF, Nieto Y, **Shah ND**, Parmar S, Bashir Q, Ahmed S, Jones RB, Kebriaei P, Olson AL, Shpall EJ, Alousi AM, Qazilbash MH, Champlin RE, Popat U. Outcomes in hepatitis C virus seropositive lymphoma and myeloma patients after autologous stem cell transplantation. *Bone Marrow Transplant*. 2016 Jul;51(7):999-1001. doi: 10.1038/bmt.2016.28. Epub 2016 Mar 7.
65. Sekine T, Marin D, Cao K, Li L, Mehta P, Shaim H, Sobieski C, Jones R, Oran B, Hosing C, Rondon G, Alsuliman A, Paust S, Andersson B, Popat U, Kebriaei P, Muftuoglu M, Basar R, Kondo K, Nieto Y, **Shah N**, Olson A, Alousi A, Liu E, Sarvaria A, Parmar S, Armstrong-James D, Imahashi N, Molldrem J, Champlin R, Shpall EJ, Rezvani K. Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation. *Blood*. 2016 Jul 14;128(2):297-312. doi: 10.1182/blood-2016-03-706317. Epub 2016 May 31.
66. Palmer J, McCune JS, Perales MA, Marks D, Bubalo J, Mohty M, Wingard J, Paci A, Hassan M, Bredeson C, Pidales J, **Shah N**, Shaughnessy P, Majhail N, Schriber J, Savani BN, Carpenter PA. Personalizing Busulfan-Based Conditioning: Considerations From the American Society for Blood and Marrow Transplantation Practice Guidelines Committee. *Biol*

- Blood Marrow Transplant. 2016 Jul 29. pii: S1083-8791(16)30249-X. doi: 10.1016/j.bbmt.2016.07.013. [Epub ahead of print].
67. Mian I, Milton DR, **Shah N**, Nieto Y, Popat UR, Kebriaei P, Parmar S, Oran B, Shah JJ, Manasanch EE, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH, Bashir Q. Prolonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myeloma. *Cancer*. 2016 Dec 15; 122(24):3831-3837.
 68. Bock F, Lu G, Srour SA, Gaballa S, Lin HY, Baladandayuthapani V, Honhar M, Stich M, **Shah ND**, Bashir Q, Patel K, Popat U, Hosing C, Korbling M, Delgado R, Rondon G, Shah JJ, Thomas SK, Manasanch EE, Isermann B, Orlowski RZ, Champlin RE, Qazilbash MH. Outcomes of patients with multiple myeloma and CKS1B gene amplification after autologous hemtopoietic stem cell transplant. *Biol Blood Marrow Transplant*. 2016 Dec 22(12):2159-2164.
 69. Kebriaei P, Bassett R, Lyons G, Valdez B, Ledesma C, Rondon G, Oran B, Ciurea S, Alousi A, Popat U, Patel K, Ahmed S, Olson A, Bashir Q, **Shah N**, Jones R, Marin D, Rezvani K, Nieto Y, Khouri I, Qazilbash M, Hosing C, Shpall E, Champlin RE, Andersson BS. Clofarabine plus busulfan is and effective conditioning regimen for allogeneic hematopoietic stem cell transplantation in patients with acute lymphoblastic leukemia: long-term study results. *Biol Blood Marrow Transplant* 2016 Nov 2. [Epub ahead of print].
 70. Badar T, Srour S, Bashir Q, **Shah N**, Al-Atrash G, Hosing C, Popat U, Nieto Y, Orlowski RZ, Champlin R, Qazilbash MH. Predictors of inferior clinical outcome in patients with standard-risk multiple myeloma. *Eur J Haematol*. 2016 Nov 9. [Epub ahead of print].
 71. **Shah N**, Li L, Mccarty J, Kaur I, Yvon E, Shaim H, Muftuoglu M, Liu E, Sobeiski C, Orlowski R, Cooper L, Lee D, Parmar S, Cao K, Hosing C, Ahmed S, Nieto Y, Bashir Q, Patel K, Bollard C, McNiece I, Qazilbash M, Champlin R, Rezvani K, Shpall EJ. Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma; *Br J Haematol*. 2017 Mar 14. doi: 10.1111/bjh.14570. [Epub ahead of print]
 72. Varma A, Biritxinaga L, Saliba RM, Stich M, Jauch SF, Afrough A, Honhar M, Popat UR, Shafi MA, **Shah N**, Bashir Q, Dinh Y, Hosing C, Champlin RE, Qazilbash MH. Impact of Hepatitis B Core Antibody Seropositivity on the Outcome of Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. *Biol Blood Marrow Transplant*. 2017 Apr;23(4):581-587. doi: 10.1016/j.bbmt.2017.01.005. Epub 2017 Jan 4.
 73. Ge I, Saliba RM, Maadani F, Popat UR, Qazilbash MH, Ravi Pingali S, **Shah N**, Ahmed S, Bashir Q, Nieto Y, Champlin RE, Hosing C. Patient age and number of apheresis days may predict development of secondary myelodysplastic syndrome and acute myelogenous leukemia after high-dose chemotherapy and autologous stem cell transplantation for lymphoma. *Transfusion*. 2017 Apr;57(4):1052-1057. doi: 10.1111/trf.14016. Epub 2017 Feb 10.
 74. Veltri LW, Milton DR, Delgado R, **Shah N**, Patel K, Nieto Y, Kebriaei P, Popat UR, Parmar S, Oran B, Ciurea S, Hosing C, Lee HC, Manasanch E, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH, Bashir Q. Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma. *Cancer*. 2017 May 17. doi: 10.1002/cncr.30770. [Epub ahead of print]
 75. Nieto Y, Valdez BC, Pingali SR, Bassett R, Delgado R, Nguyen J, **Shah N**, Popat U, Jones RB, Andersson BS, Gulbis A, Ahmed S, Bashir Q, Parmar S, Patel K, Myers A, Rondon G, Orlowski RZ, Champlin R, Qazilbash M. High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan. *Lancet Haematol*. 2017 Jun;4(6):e283-e292. doi: 10.1016/S2352-3026(17)30080-7. Epub 2017 May 15.
 76. Mohyuddin GR, Faisal MS, Badar T, **Shah N**, Bashir Q, Patel KK, Hosing C, Popat UR, Rondon G, Delgado R, Shah JJ, Weber DM, Thomas SK, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH. A case control study of syngeneic transplantation versus autologous transplantation for multiple myeloma: two decades of experiences from a single center. *Leuk Lymphoma*. 2017 Jul 3:1-4. doi: 10.1080/10428194.2017.1344906. [Epub ahead of print]

77. Im JS, Abraham SC, Saliba RM, Rondon G, Ross WA, Rashid A, Shpall EJ, Popat U, Qazilbash MH, Hosing C, Oran B, **Shah N**, Tewari P, Nieto Y, Kebriaei P, Champlin RE, Alousi AM. Histologic Grade 1 Is Associated With Increased Nonrelapsed Mortality in Lower Gastrointestinal Graft Versus Host Disease. *Am J Surg Pathol*. 2017 Nov;41(11):1483-1490. doi: 10.1097/PAS.0000000000000914.
78. **Shah N**, Cornelison AM, Saliba R, Ahmed S, Nieto YL, Bashir Q, Parmar S, Hosing C, Popat U, Shpall EJ, Champlin RE, Qazilbash M. Inpatient vs outpatient autologous hematopoietic stem cell transplantation for multiple myeloma. *Eur J Haematol*. 2017 Dec;99(6):532-535. doi: 10.1111/ejh.12970. Epub 2017 Oct 8
79. **Shah N**, Shi Q, Giralt S, Williams L, Bashir Q, Qazilbash M, Champlin RE, Cleeland CS, Wang XS. Utility of a patient-reported outcome in measuring functional impairment during autologous stem cell transplant in patients with multiple myeloma. *Qual Life Res*. 2017 Dec 19. doi: 10.1007/s11136-017-1759-2. [Epub ahead of print].
80. Ragon BK, Mehta RS, Gulbis AM, Saliba RM, Chen J, Rondon G, Popat UR, Nieto Y, Oran B, Olson AL, Patel K, Hosing CM, Qazilbash MH, **Shah N**, Kebriaei P, Shpall EJ, Champlin RE, Alousi AM. Pentostatin therapy for steroid-refractory acute graft versus host disease: identifying those who may benefit. *Bone Marrow Transplant*. 2017 Dec 21. doi: 10.1038/s41409-017-0034-z. [Epub ahead of print]
81. Lacourt TE, Kavelaars A, Galloway-Peña JR, Sahasrabhojane PV, **Shah ND**, Futreal A, Kontoyiannis DP, Shelburne SA, Heijnen CJ. Associations of inflammation with symptom burden in patients with acute myeloid leukemia. *Psychoneuroendocrinology*. 2018 Mar;89:203-208. doi: 10.1016/j.psyneuen.2018.01.018.
82. Hashmi SK, Lee SJ, Savani BN, Burns L, Wingard JR, Perales MA, Palmer J, Chow E, Meyer E, Marks D, Mohty M, Inamoto Y, Rodriguez C, Nagler A, Sauter C, Komanduri KV, Pidala J, Hamadani M, Johnston L, **Shah N**, Shaughnessy P, Hamilton BK, Majhail N, Kharfan-Dabaja MA, Schriber J, DeFilipp Z, Tarlock KG, Fanning S, Curtin P, Rizzo JD, Carpenter PA. ASBMT Practice Guidelines Committee Survey on Long-Term Follow-Up Clinics for Hematopoietic Cell Transplant Survivors. *Biol Blood Marrow Transplant*. 2018 Jun;24(6):1119-1124. doi: 10.1016/j.bbmt.2018.03.023. Epub 2018 Mar 30.
83. Hu B, Thall P, Milton DR, Sasaki K, Bashir Q, **Shah N**, Patel K, Popat U, Hosing C, Nieto Y, Lin P, Delgado R, Jorgensen J, Manasanch E, Weber D, Thomas S, Orlowski RZ, Champlin R, QazilbashMH. High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes. *Leuk Lymphoma*. 2018 Jul 22:1-11. doi: 10.1080/10428194.2018.1485908. [Epub ahead of print]
84. Lacourt TE, Kavelaars A, Ohanian M, **Shah ND**, Shelburne SA, Futreal A, Kontoyiannis DP, Heijnen CJ. Patient-reported fatigue prior to treatment is prognostic of survival in patients with acute myeloid leukemia. *Oncotarget*. 2018 Jul 27;9(58):31244-31252. doi: 10.18632/oncotarget.25787. eCollection 2018 Jul 27.
85. Afrough A, Saliba RM, Hamdi A, Honhar M, Varma A, Cornelison AM, Rondon G, Parmar S, **Shah ND**, Bashir Q, Hosing C, Popat U, Weber DM, Thomas S, Orlowski RZ, Champlin RE, Qazilbash MH. Impact of Induction Therapy on the Outcome of Immunoglobulin Light Chain Amyloidosis after Autologous Hematopoietic Stem Cell Transplantation. *Biol Blood Marrow Transplant*. 2018 Nov;24(11):2197-2203. doi: 10.1016/j.bbmt.2018.07.010. Epub 2018 Aug 9.
86. Scott EC, Hari P, Kumar S, Fraser R, Davila O, **Shah N**, Gale RP, Diaz MA, Agrawal V, Cornell RF, Ganguly S, Akpek G, Freytes C, Hashmi S, Malek E, Kamble RT, Lazarus H, Solh M, Usmani SZ, Kanate AS, Saad A, Chhabra S, Gergis U, Cerny J, Kyle RA, Lee C, Kindwall-Keller T, Assal A, Hildebrandt GC, Holmberg L, Maziarz RT, Nishihori T, Seo S, Kumar S, Mark T, D'Souza A. Staging Systems for Newly Diagnosed Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation: The Revised International Staging System Shows the Most Differentiation between Groups. *Biol Blood Marrow Transplant*. 2018 Dec;24(12):2443-2449. doi: 10.1016/j.bbmt.2018.08.013. Epub 2018 Aug 22.
87. Popat UR, Mehta RS, Bassett R, Chen J, Valdez BC, Kawedia J, Ahmed S, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Jones R, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Parmar S, Rezvani K, Qazilbash MH, **Shah N**,

- Srouf SA, Shpall EJ, Champlin RE, Andersson BS. Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial. *Lancet Haematol*. 2018 Nov;5(11):e532-e542. doi: 10.1016/S2352-3026(18)30156-X.
88. Gowda L, Shah M, Badar I, Bashir Q, **Shah N**, Patel K, Kanagal-Shamanna R, Mehta R, Weber DM, Lee HC, Manasanch EE, Shah A, Thomas SK, Parmar S, Nieto Y, Orlowski RZ, Champlin R, Qazilbash MH. Primary plasma cell leukemia: autologous stem cell transplant in an era of novel induction drugs. *Bone Marrow Transplant*. 2018 Nov 16. doi: 10.1038/s41409-018-0392-1. [Epub ahead of print]
 89. Gopalakrishnan S, D'Souza A, Scott E, Fraser R, Davila O, **Shah N**, Gale RP, Kamble R, Diaz MA, Lazarus HM, Savani BN, Hildebrandt GC, Solh M, Freytes CO, Lee C, Kyle RA, Usmani SZ, Ganguly S, Assal A, Berdeja J, Kanate AS, Dhakal B, Meehan K, Kindwall-Keller T, Saad A, Locke F, Seo S, Nishihori T, Gergis U, Gasparetto C, Mark T, Nieto Y, Kumar S, Hari P. Revised-International Staging System (R-ISS) is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma (MM). *Biol Blood Marrow Transplant*. 2018 Dec 20. pii: S1083-8791(18)30963-7. doi: 10.1016/j.bbmt.2018.12.141. [Epub ahead of print]
 90. Maymani H, Lin P, Saliba RM, Popat U, Bashir Q, **Shah N**, Patel K, Parmar S, Kebriaei P, Hosing C, Ciurea S, Andersson B, Shpall E, Champlin R, Srouf SA, Qazilbash MH. Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning Regimens. *Biol Blood Marrow Transplant*. 2019 Jan 11. pii: S1083-8791(19)30024-2. doi: 10.1016/j.bbmt.2019.01.009. [Epub ahead of print]
 91. Stadtmauer EA, Pasquini MC, Blackwell B, Hari P, Bashey A, Devine S, Efebera Y, Ganguly S, Gasparetto C, Geller N, Horowitz MM, Koreth J, Knust K, Landau H, Brunstein C, McCarthy P, Nelson C, Qazilbash MH, **Shah N**, Vesole DH, Vij R, Vogl DT, Giralt S, Somlo G, Krishnan A. Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma. *J Clin Oncol*. 2019 Jan 17;JCO1800685. doi: 10.1200/JCO.18.00685. [Epub ahead of print]
 92. Gopalakrishnan S, D'Souza A, Scott E, Fraser R, Davila O, **Shah N**, Gale RP, Kamble R, Diaz MA, Lazarus HM, Savani BN, Hildebrandt GC, Solh M, Freytes CO, Lee C, Kyle RA, Usmani SZ, Ganguly S, Assal A, Berdeja J, Kanate AS, Dhakal B, Meehan K, Kindwall-Keller T, Saad A, Locke F, Seo S, Nishihori T, Gergis U, Gasparetto C, Mark T, Nieto Y, Kumar S, Hari P. Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma. *Biol Blood Marrow Transplant*. 2019 Apr;25(4):683-688. doi: 10.1016/j.bbmt.2018.12.141. Epub 2018 Dec 21. PMID: 30579965
 93. Scott EC, Hari P, Kumar S, Fraser R, Davila O, **Shah N**, Gale RP, Diaz MA, Agrawal V, Cornell RF, Ganguly S, Akpek G, Freytes C, Hashmi S, Malek E, Kamble RT, Lazarus H, Solh M, Usmani SZ, Kanate AS, Saad A, Chhabra S, Gergis U, Cerny J, Kyle RA, Lee C, Kindwall-Keller T, Assal A, Hildebrandt GC, Holmberg L, Maziarz RT, Nishihori T, Seo S, Kumar S, Mark T, D'Souza A. Staging Systems for Newly Diagnosed Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation: The Revised International Staging System Shows the Most Differentiation between Groups. *Biol Blood Marrow Transplant*. 2018 Dec;24(12):2443-2449. doi: 10.1016/j.bbmt.2018.08.013. Epub 2018 Aug 22. PMID: 30142419
 94. Ghobrial I, Cruz CH, Garfall A, **Shah N**, Munshi N, Kaufman J, Boise LH, Morgan G, Adalsteinsson VA, Manier S, Pillai R, Malavasi F, Lonial S. Immunotherapy in Multiple Myeloma: Accelerating on the Path to the Patient. *Clin Lymphoma Myeloma Leuk*. 2019 Feb 20. pii: S2152-2650(18)31257-6. doi: 10.1016/j.clml.2019.02.004. [Epub ahead of print] Review. PMID: 31023594
 95. Bashir Q, Thall PF, Milton DR, Fox PS, Kawedia JD, Kebriaei P, **Shah N**, Patel K, Andersson BS, Nieto YL, Valdez BC, Parmar S, Rondon G, Delgado R, Hosing C, Popat UR, Oran B, Ciurea SO, Lin P, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Williams LA, Champlin RE, Qazilbash MH. Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma:

- an open-label, randomised, phase 3 trial. *Lancet Haematol*. 2019 May;6(5):e266-e275. doi: 10.1016/S2352-3026(19)30023-7. Epub 2019 Mar 22. PMID: 30910541
96. Sully K, Trigg A, Bonner N, Moreno-Koehler A, Trennery C, **Shah N**, Yucel E, Panjabi S, Cocks K. Estimation of minimally important differences and responder definitions for EORTC QLQ-MY20 scores in multiple myeloma patients. *Eur J Haematol*. 2019 Aug 24. doi: 10.1111/ejh.13316. [Epub ahead of print]
 97. Sidana S and **Shah N**. CAR-T Therapy- Is it Prime-Time in Myeloma? *Blood Adv*. 2019 Nov 12;3(21):3473-3480. doi: 10.1182/bloodadvances.2019000370
 98. Choudhry P, Mariano MC, Geng H, Martin TG, Wolf JL, Wong SW, **Shah N**, Wiita AP. DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma. *Leukemia*, 2020 Mar;34(3):938-941. doi: 10.1038/s41375-019-0587-5. Epub 2019 Oct 8.
 99. Fakhri B, Fiala MA, **Shah N**, Vij R, Wildes T. Measuring cardiopulmonary complications of carfilzomib treatment and associated risk factors using the SEER-Medicare Database. *Cancer* 2019, (in press).
 100. **Shah N**, Chari A, Scott E, Mezzi K, Usmani S. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. *Leukemia*, in press
 101. Kambhampati S, Galligan D, Huang CY, Wong S, Wolf J, Martin T, **Shah N**. A single-center retrospective cohort analysis of venetoclax in relapsed/refractory multiple myeloma. *Leuk Lymphoma*. 2020 Jan 11:1-9. doi: 10.1080/10428194.2019.1709835. [Epub ahead of print]
 102. Huang HH, Ferguson ID, Thornton AM, Lam C, Lin Y, Bastola P, Choudhry P, Mariano MC, Marcoulis M, Malato J, Phojanakong P, Martin TG, Wolf JL, Wong SW, **Shah N**, Hann BC, Brooks CN, Wiita AP. Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma. *Nat Commun* (2020), in press.
 103. Efebera YA, **Shah N**. Fixed-Duration Versus Until Disease Progression: How Long Should Initial Treatment of Multiple Myeloma Last? *J Natl Compr Canc Netw*. 2019 Nov;17(11.5):1430-1432. doi: 10.6004/jnccn.2019.5033.
 104. Shah EE, Young RP, Wong SW, Damon LE, Wolf JL, **Shah ND**, Leavitt AD, Loeffler P, Martin TG. Impact of Plerixafor Use at Different Peripheral Blood CD34+ Thresholds on Autologous Stem Cell Collection in Patients with Multiple Myeloma. *Biol Blood Marrow Transplant*. 2019 Nov 27. pii: S1083-8791(19)30830-4. doi: 10.1016/j.bbmt.2019.11.024. [Epub ahead of print]
 105. Voorhees PM, Kaufman JL, Laubach JP, Sborov DW, Reeves B, Rodriguez C, Chari A, Silbermann R, Costa LJ, Anderson LD, Nathwani N, **Shah N**, Efebera YA, Holstein SA, Costello C, Jakubowiak A, Wildes T, Orlowski RZ, Shain KH, Cowan AJ, Murphy SP, Lutska Y, Pei H, Ukropec J, Vermeulen J, de Boer C, Hoehn D, Lin T, Richardson PG. Daratumumab, Lenalidomide, Bortezomib, & Dexamethasone for Transplant-eligible Newly Diagnosed Multiple Myeloma: GRIFFIN. *Blood*. 2020 Apr 23. PMID: 32325490.
 106. Cedena MT, Martin-Clavero E, Wong S, **Shah N**, Bahri N, Alonso R, Barcenas C, Valeri A, Salazar Tabares J, Sanchez-Pina J, Cuellar C, Martin T, Wolf J, Lahuerta JJ, Martinez-Lopez J. The clinical significance of stringent complete response in multiple myeloma is surpassed by minimal residual disease measurements. *PLoS One* 2020 Aug 31;15(8):e0237155. doi:10.1371/journal.pone.0237155. eCollection 2020.
 107. Narayan R, Galligan D, Lazar AA, Kim S, Fong R, Tan M, Lo M, Arora S, **Shah N**, Wong SW, Martin T, Wolf J. Modified Hyper-CVAD With Proteasome Inhibition for Multiple Myeloma: A Single-Center Retrospective Analysis. *Clin Lymphoma Myeloma Leuk* 2020 Dec;20(12):e961-e985. doi: 10.1016/j.clml.2020.07.015. Epub 2020 Jul 29.
 108. Martinez-Lopez J, Wong SW, **Shah N**, Bahri N, Zhou K, Sheng Y, Huang CY, Martin T, Wolf J. Clinical value of measurable residual disease testing for assessing depth, duration, and direction of response in multiple myeloma. *Blood Adv*. 2020 Jul 28;4(14):3295-3301. doi: 10.1182/bloodadvances.2020002037.
 109. Ramkumar P, Abarientos AB, Tian R, Seyler M, Leong JT, Chen M, Choudhry P, Hechler T, **Shah N**, Wong SW, Martin TG, Wolf JL, Roybal KT, Pahl A, Taunton J, Wiita AP, Kampmann M. CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma. *Blood Adv*. 2020 Jul 14;4(13):2899-2911.

110. Alonso R, Cedena MT, Wong S, **Shah N**, Ríos-Tamayo R, Moraleda JM, López-Jiménez J, García C, Bahri N, Valeri A, Sánchez R, Collado-Yurrita L, Martin T, Wolf J, Lahuerta JJ, Martínez-López J. Prolonged lenalidomide maintenance therapy improves the depth of response in multiple myeloma. *Blood Adv.* 2020 May 26;4(10):2163-2171. doi: 10.1182/bloodadvances.2020001508.
111. Badar T, Hari P, Dávila O, Fraser R, Wirk B, Dhakal B, Freytes CO, Rodriguez Valdes C, Lee C, Vesole DH, Malek E, Hildebrandt GC, Landau H, Murthy HS, Lazarus HM, Berdeja JG, Meehan KR, Solh M, Diaz MA, Kharfan-Dabaja MA, Callander NS, Farhadfar N, Bashir Q, Kamble RT, Vij R, Munker R, Kyle RA, Chhabra S, Hashmi S, Ganguly S, Jagannath S, Nishihori T, Nieto Y, Kumar S, **Shah N**, D'Souza A. African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United States. *Cancer.* 2020 Jan 1;127(1):82-92. doi: 10.1002/cncr.33208. Epub 2020 Sep 23.
112. Dhakal B, D'Souza A, Callander N, Chhabra S, Fraser R, Davila O, Anderson K, Assal A, Badawy SM, Berdeja J, Cerny J, Comenzo R, Chakraborty R, Peter Gale R, Kamble R, Kharfan-Dabaja MA, Krem M, Ganguly S, Janakiram M, Kansagra A, Munker R, Murthy H, Patel S, Kumar S, **Shah N**, Qazilbash M, Hari P. Novel prognostic scoring system for autologous hematopoietic cell transplantation in multiple myeloma. *Br J Haematol.* 2020 Nov;191(3):442-452. doi: 10.1111/bjh.16987. Epub 2020 Oct 23. PMID: 33094839
113. Holstein SA, Howard A, Avigan D, Bhutani M, Cohen AD, Costa LJ, Dhodapkar MV, Gay F, Gormley N, Green DJ, Hillengass J, Korde N, Li Z, Mailankody S, Neri P, Parekh S, Pasquini MC, Puig N, Roodman GD, Samur MK, **Shah N**, Shah UA, Shi Q, Spencer A, Suman VJ, Usmani SZ, McCarthy PL. Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling. *Biol Blood Marrow Transplant* 2020 Oct;26(10):e247 Epub 2020 Jun 24.
114. Munshi PN, Vesole D, Jurczynszyn A, Zaucha JM, St Martin A, Davila O, Agrawal V, Badawy SM, Battiwalla M, Chhabra S, Copelan E, Kharfan-Dabaja MA, Farhadfar N, Ganguly S, Hashmi S, Krem MM, Lazarus HM, Malek E, Meehan K, Murthy HS, Nishihori T, Olin RL, Olsson RF, Schriber J, Seo S, Shah G, Solh M, Tay J, Kumar S, Qazilbash MH, **Shah N**, Hari PN, D'Souza A. Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma. *Cancer.* 2020 Dec 1;126(23):5077-5087. doi: 10.1002/cncr.33171. Epub 2020 Sep 23. PMID: 32965680
115. **Shah N**, Aiello J, Avigan DE, Berdeja JG, Borrello IM, Chari A, Cohen AD, Ganapathi K, Gray L, Green D, Krishnan A, Lin Y, Manasanch E, Munshi NC, Nooka AK, Rapoport AP, Smith EL, Vij R, Dhodapkar M. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma. 2020 Jul;8(2):e000734. doi: 10.1136/jitc-2020-000734.
116. Baik A, Oluwole OO, Johnson DB, **Shah N**, Salem, JE, Tsai K, Moslehi JJ, Mechanisms of Cardiovascular Toxicities Associated with Immunotherapies Circulation Research. In press.
117. Parks AL, Kambhampati S, Fakhri B, Andreadis C, Gray L, Wong SW, **Shah N**, Fang MC. Incidence, Management and Outcomes of Arterial and Venous Thrombosis After Chimeric Antigen Receptor Modified T Cells for B Cell Lymphoma and Multiple Myeloma. *Leuk Lymphoma.* 2020 Dec 1:1-6. doi: 10.1080/10428194.2020.1852474. Online ahead of print.
118. Banerjee R, Lazar A, Dunn L, Knoche J, Lo M, Arora S, Wong S, Wolf J, Martin T, Dhruva A, **Shah N**. Benzodiazepine & Zolpidem Prescriptions during Autologous Stem Cell Transplantation. *European Journal of Haematology.* In press.
119. Martin T, **Shah N**, Richter J, Vesole D, Wong SW, Huang C, Madduri D, Jagannath S, Seigel D, Biran N, Wolf J, Parekh S, Cho HJ, Munster P, Richard S, Campana F, and Chari A. Phase 1b Trial of Isatuximab, an Anti-CD38 Monoclonal Antibody, in Combination with Carfilzomib as Treatment of Relapsed/ Refractory Multiple Myeloma. *Cancer*; In press.

Invited Articles

1. Cany J, Dolstra H, **Shah N**. Umbilical cord blood-derived cellular products for cancer immunotherapy. *Cytotherapy* 17(6):739-748, 6/2015. e-Pub 3/2015. PMID: 25795272.

Editorials

1. **Shah N**, Shpall EJ. NK antibody therapy: KIR-active intent. *Blood* 114(13):2567-8, 9/2009. PMID: 19779042.
2. **Shah N**. Activating KIR: iN Kase of KIR-ligand mismatch. *Blood* 125(20):3045-6, 5/2015. PMID: 25977581.
3. **Shah N**, Boelens JJ. Umbilical cord blood: advances and opportunities. *Cytotherapy* 17(6):693-4, 6/2015. PMID: 25946725.
4. **Shah, N**. Cellular Therapy for Multiple Myeloma: A Cause for Cautious Optimism. *ASCO Daily News*, February 6, 2019
5. **Shah N**. The Struggle Is Real: Practice Patterns for the "Myelennial" Generation. *JCO Oncol Pract*. 2020 Jan;16(1):17-18. doi: 10.1200/JOP.19.00728.

Other Articles

N/A

Book Chapters

1. **Shah N**, Avery TP, Fu W, Weber D, Lu G, Lin P, Qazilbash M, Wang M. Myeloma and Other Plasma Cell Dyscrasias. In: M. D. Anderson Manual of Medical Oncology, 2nd. Ed(s) James Shanahan and Cindy Yoo. The McGraw-Hill Companies: Houston, Texas, 245-282, 2011. PMID: 978-0-07-170106-8.
2. El Fakh R, **Shah N**, Nieto Y. Autologous stem cell transplants. In: M.D. Anderson Manual of Medical Oncology, 3e; 2016.
3. Fakhri, B and **Shah, N**. Allogeneic hematopoietic stem cell transplant for multiple myeloma. *Therapeutic Advances in Multiple Myeloma: A Clinical Guide*. Springer Nature (in press).

Books (edited and written)

N/A

Letters to the Editor

N/A

Manuals, Teaching Aids, Other Teaching Publications

N/A

Other Publications

N/A

EDITORIAL AND REVIEW ACTIVITIES

Editor/Service on Editorial Board(s)

Editorial Board Member, *Leukemia and Lymphoma*, July 1, 2014 - June 2017 Editors-in-Chief, Professors Aaron Polliack, Koen Van Besien and John Seymour, 2014-2017

Contributing Editor, *Journal of Patient-Centered Research & Reviews*; 2017-present

Editor, *Cytotherapy: Special Issue on Umbilical Cord Blood*, 2015

Member of Editorial Review Board

N/A

Journal Reviewer

Reviewer, *Blood*, 2000

Reviewer, *Leukemia and Lymphoma*, 2000-present

Reviewer, *Clinical Lymphoma, Myeloma and Leukemia*, 2012-present

Reviewer, *Biology of Blood and Marrow Transplantation*, 2015-present

Reviewer, Bone Marrow Transplantation, 2015-present

Reviewer, Cancer Research, 2015-present

Other Editorial and Review Activities

N/A

TEACHING

Teaching Within Current Institution - University of California San Francisco

Formal Teaching

Courses Taught

Faculty, Cancer Immunotherapy Program Mini Course, 2018-present

Teaching at Prior Institutions

Formal Teaching

Courses Taught

Training Programs

N/A

Other Formal Teaching

N/A

Supervisory Teaching

Committees

Advisory Committees

N/A

Supervisory Committees

N/A

Examining Committees

N/A

Direct Supervision

Undergraduate and Allied Health Students

N/A

Medical Students

N/A

Graduate Students

N/A

Postdoctoral Research Fellows

N/A

Clinical Residents and Fellows

DoCM Hematology-Oncology Fellows, Hematology-Oncology Fellows, 2014-present

Stem Cell Transplantation In-Patient and Continuity Clinic, Ravin Ratan, MD, 2012

UCSF Hematology-Oncology Fellows, 2017-present

Other Supervisory Teaching

N/A

Teaching

N/A

PROFESSIONAL MEMBERSHIPS/ACTIVITIES

Professional Society Activities, with Offices Held

National and International

American Society of Clinical Oncology

Member, 2008-present

American Society of Hematology
Member, 2008-present

American Society of Hematology, Clinical Research Training Institute Steering Committee
Member, 2011-2012

American Society for Blood and Marrow Transplantation for Practice Guidelines
Committee Member, 2012-present

American Society for Blood and Marrow Transplantation, BMT CTN Myeloma Intergroup
Committee Member, 2015-present

American Society for Blood and Marrow Transplantation, BMT CTN-0702 Endpoint Review
Committee
Committee Member, 2015-present

American Society of Hematology, Clinical Research Training Institute Faculty
2015-2017

American Society of Hematology News Daily Editorial Board 2017

Center for International Blood and Marrow Transplant Research
Plasma Cell Disorder and Adult Solid Tumor Working Committee Co-chair, 2018-present

American Society of Hematology
Scientific Committee on Plasma Cell Neoplasia, 2019-2022

Society for Immunotherapy of Cancer
Co-Chair, Multiple Myeloma Cancer Immunotherapy Guidelines Committee, 2019-
present

American Society of Clinical Oncology Women's Networking Center Committee 2019-present

American Society for Blood and Marrow Transplantation, BMT CTN-1401 Endpoint Review
Committee 2020-present

Local/State

N/A

UNIQUE ACTIVITIES

Inaugural Co-Chair, Leadership Empowerment and Development Workshop for women in oncology,
2019-present